Matches in SemOpenAlex for { <https://semopenalex.org/work/W3031471749> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W3031471749 endingPage "1299" @default.
- W3031471749 startingPage "1296" @default.
- W3031471749 abstract "Objective To compare the clinical efficacy of intravitreal triamcinolone acetonide (TA)and intravitreal bevacizumab for diabetic macular edema (DME). Methods In a total of 68 cases (82 eyes)with DME who underwent routine ocular examination and optic coherence tomography were enrolled in this study. The patients were divided into two groups for intravitreal TA (4mg, 0.1ml) or intravitreal bevacizumab (1.25mg, 0.05ml) injection. The difference of age, diabetes duration, macular edema duration, best corrected visual acuity (BCVA), central macular thickness (CMT) and intraocular pressure between TA group (37 cases, 45eyes) and bevacizumab group (31 cases, 37 eyes) were insignificant. The change ofBCVA, CMT and intraocular pressure at 4-week, 8-week and 12-week follow-up between the two groups were compared. Results At the 4-week, 8-week and 12-week follow-up, the change of BCVA between TA group and bevacizumab group did not vary significantly (t =-0.316, 0.896, and 0.879; P =0.754, 0.389 and 0.384, respectively). At 4-week and 12-week follow-up, the reduction of macular edema in TA group was significantly higher than bevacizumab group (t =-1.892 and -3.007; P =0.036 and 0.004, respectively). At the 8-week follow-up, the reduction of macular edema between two groups were insignificant (t =-0.362; P =0.722). At the 8-week and 12-week follow-ups, intraocular pressure in TA group were significantly higher than bevacizumab group (t =2.334 and 2.600; P =0.026 and 0.015, respectively). Conclusions Intravitreal injection of triamcinolone acetonide is more effective than intravitreal injection of bevacizumab in reducing the thickness of macular edema. Moreover, the efficacy ofintravitreal TA last for a longer time than bevacizumab. Randomized, control and multicenter study with large scale patients is needed.Key words: Triamcinolone Acetonide; Bevacizumab; Diabetic retinopathy; Macular edema" @default.
- W3031471749 created "2020-06-05" @default.
- W3031471749 creator A5007332794 @default.
- W3031471749 creator A5050985047 @default.
- W3031471749 date "2010-12-10" @default.
- W3031471749 modified "2023-09-23" @default.
- W3031471749 title "Intravitreal injection of triamcinolone acetonide versus bevacizumab for diabetic macular edema" @default.
- W3031471749 doi "https://doi.org/10.3760/cma.j.issn.1006-4443.2010.012.006" @default.
- W3031471749 hasPublicationYear "2010" @default.
- W3031471749 type Work @default.
- W3031471749 sameAs 3031471749 @default.
- W3031471749 citedByCount "0" @default.
- W3031471749 crossrefType "journal-article" @default.
- W3031471749 hasAuthorship W3031471749A5007332794 @default.
- W3031471749 hasAuthorship W3031471749A5050985047 @default.
- W3031471749 hasConcept C118487528 @default.
- W3031471749 hasConcept C134018914 @default.
- W3031471749 hasConcept C141071460 @default.
- W3031471749 hasConcept C2776251621 @default.
- W3031471749 hasConcept C2776694085 @default.
- W3031471749 hasConcept C2777802072 @default.
- W3031471749 hasConcept C2778257484 @default.
- W3031471749 hasConcept C2778903070 @default.
- W3031471749 hasConcept C2779829184 @default.
- W3031471749 hasConcept C2780347916 @default.
- W3031471749 hasConcept C2780886150 @default.
- W3031471749 hasConcept C2781092963 @default.
- W3031471749 hasConcept C2985127711 @default.
- W3031471749 hasConcept C555293320 @default.
- W3031471749 hasConcept C71924100 @default.
- W3031471749 hasConceptScore W3031471749C118487528 @default.
- W3031471749 hasConceptScore W3031471749C134018914 @default.
- W3031471749 hasConceptScore W3031471749C141071460 @default.
- W3031471749 hasConceptScore W3031471749C2776251621 @default.
- W3031471749 hasConceptScore W3031471749C2776694085 @default.
- W3031471749 hasConceptScore W3031471749C2777802072 @default.
- W3031471749 hasConceptScore W3031471749C2778257484 @default.
- W3031471749 hasConceptScore W3031471749C2778903070 @default.
- W3031471749 hasConceptScore W3031471749C2779829184 @default.
- W3031471749 hasConceptScore W3031471749C2780347916 @default.
- W3031471749 hasConceptScore W3031471749C2780886150 @default.
- W3031471749 hasConceptScore W3031471749C2781092963 @default.
- W3031471749 hasConceptScore W3031471749C2985127711 @default.
- W3031471749 hasConceptScore W3031471749C555293320 @default.
- W3031471749 hasConceptScore W3031471749C71924100 @default.
- W3031471749 hasIssue "12" @default.
- W3031471749 hasLocation W30314717491 @default.
- W3031471749 hasOpenAccess W3031471749 @default.
- W3031471749 hasPrimaryLocation W30314717491 @default.
- W3031471749 hasRelatedWork W1982460180 @default.
- W3031471749 hasRelatedWork W1994973534 @default.
- W3031471749 hasRelatedWork W1999343243 @default.
- W3031471749 hasRelatedWork W2022462690 @default.
- W3031471749 hasRelatedWork W2032687057 @default.
- W3031471749 hasRelatedWork W2063385448 @default.
- W3031471749 hasRelatedWork W2064500194 @default.
- W3031471749 hasRelatedWork W2070126836 @default.
- W3031471749 hasRelatedWork W2150171454 @default.
- W3031471749 hasRelatedWork W2171529843 @default.
- W3031471749 hasRelatedWork W2186450107 @default.
- W3031471749 hasRelatedWork W221049470 @default.
- W3031471749 hasRelatedWork W2301514247 @default.
- W3031471749 hasRelatedWork W2371985479 @default.
- W3031471749 hasRelatedWork W2617278514 @default.
- W3031471749 hasRelatedWork W2941401484 @default.
- W3031471749 hasRelatedWork W2991960168 @default.
- W3031471749 hasRelatedWork W3028876739 @default.
- W3031471749 hasRelatedWork W3030400076 @default.
- W3031471749 hasRelatedWork W3031362069 @default.
- W3031471749 hasVolume "28" @default.
- W3031471749 isParatext "false" @default.
- W3031471749 isRetracted "false" @default.
- W3031471749 magId "3031471749" @default.
- W3031471749 workType "article" @default.